FDA peptide ban explained: what's actually legal in 2025?
There's a lot of confusion about what the FDA peptide restrictions actually mean. Here's a factual breakdown: **What happened:** In October 2023, the FDA placed 17 peptides on Category 2 of the bulk drug substances list, meaning they cannot be legally compounded by pharmacies for human use. **Which peptides are restricted:** BPC-157, ipamorelin, CJC-1295, GHRP-2, GHRP-6, AOD-9604, TB-500, thymosin alpha-1, epithalon, GHK-copper, MOTS-c, melanotan II, KPV, selank, semax, kisspeptin-10, and others. **What this means:** Licensed compounding pharmacies (503A and 503B) cannot legally produce these peptides for human patients. They remain available as 'research chemicals' but selling them for human consumption is technically illegal. **What it doesn't mean:** Peptides are not 'illegal to possess.' The restrictions target manufacturing and sale, not individual possession. **Legal challenges:** Compounding pharmacies sued the FDA, forcing them to reconvene the PCAC. Five peptides were removed from Category 2 in September 2024. Others remain restricted. **The RFK Jr. factor:** HHS Secretary Kennedy has signaled potential policy changes, but no formal regulatory reversal has occurred as of this writing. Bottom line: the regulatory landscape is actively evolving. What's restricted today may change. Stay informed through legitimate sources, not social media hype.
Replies (2)
Thanks for this. I was under the impression ALL peptides were banned. The distinction between what compounding pharmacies can make vs. what you can possess vs. what 'research chemical' vendors sell is important and rarely explained clearly.
I'd add that FDA-approved peptide medications (semaglutide, tirzepatide, tesamorelin, etc.) remain fully legal and available through normal prescriptions. The ban specifically targets non-approved peptides in the compounding space. There's a big difference between 'this peptide has no FDA approval' and 'this peptide is dangerous.'